ClinicalTrials.gg
RecruitingNCT07356024Updated Nov 20, 2026

Effect of Acupressure on Blood Glucose And Anxiety in Elderly With Diabetes

An interventional study of Acupressure and Sham Acupressure in Diabetes Mellitus and Acupressure, sponsored by Abant Izzet Baysal University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Abant Izzet Baysal University · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 20, 2026Now RecruitingStudy completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 246 studies in Diabetes Mellitus with a site in Turkey — 37 open to participants now, 44 under way, 1 of them phase 3. Diabetes Mellitus · Turkey.

Planned enrollment
125th of 147
48 · median 90
Started
2026
with 17 others
No phase
92 of 246
22 open now
Primary completion
2026-08
later than 28 of 43 live
Registered
224th of 246
by date
Lead sponsor
7 of 246
Abant Izzet Baysal University

Among the 246 studies in Diabetes Mellitus with a site in Turkey, this one is the 125th largest by planned enrollment of the 147 interventional ones that give a count, is one of 18 that started in 2026, is one of 92 with no phase, reaches primary completion later than 28 of the 43 other live ones, and was the 224th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

37 of the 246 studies in Diabetes Mellitus with a site in Turkey are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 65 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 246 studies in Diabetes Mellitus with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to evaluate the effects of acupressure on blood glucose levels and anxiety in older adults with diabetes. A three-arm randomized controlled trial will be conducted, comparing acupressure, sham acupressure, and routine care groups. Fasting and postprandial blood glucose levels will be assessed as primary outcomes, and state anxiety will be assessed as a secondary outcome.

Read the detailed description

Diabetes is a common chronic disease in older adults and may be associated with difficulties in maintaining optimal blood glucose levels and increased anxiety. This study is designed to evaluate the effects of acupressure on blood glucose levels and anxiety in older adults with diabetes. This is a three-arm, parallel-group, double-blind randomized controlled trial. Participants will be randomly assigned in a 1:1:1 ratio to an acupressure group, a sham acupressure group, or a routine care control group. Participants in the intervention group will receive acupressure applied to the HT7, SP6, and ST36 acupoints by a trained researcher. The intervention will be administered once daily for six sessions, with each session lasting approximately 15-20 minutes. The sham acupressure group will receive light pressure applied to non-acupoint areas near the same anatomical regions, while the control group will continue to receive routine clinical care without any additional intervention. The primary outcome of the study is blood glucose level, assessed using fasting and postprandial capillary blood glucose measurements at baseline and at predefined time points during the intervention period. Secondary outcomes include anxiety levels, measured using the State-Trait Anxiety Inventory.Outcome assessments will be conducted by assessors blinded to group allocation. Prior to the main trial, a pilot study will be conducted to evaluate the feasibility of the intervention protocol and data collection procedures, and to estimate the effect size required for calculating the final sample size of the main study. Findings from the pilot study will be used to refine the intervention procedures and to determine the final sample size. Participants included in the pilot study will not be included in the main trial.

03

Conditions studied

  • Diabetes Mellitus
  • Acupressure

Keywords

  • Randomized Controlled Trial
  • Diabetes
  • Elderly
  • Acupressure
  • Anxiety
  • Blood Glucose
04

Who can participate

The criteria were revised on the registry on Oct 9, 2026. See what changed

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being 65 years of age or older,
  • Having been diagnosed with diabetes for at least one year,
  • There should be no hearing, speech, or vision problems that would hinder the exchange and communication of the information,
  • Being able to speak and understand Turkish,
  • Not using any other complementary or supportive therapies during the study period,
  • Successfully passing the mini mental and cognitive assessment routinely performed in the clinic,
  • Continuing routine diabetes treatment for the past month.

Exclusion criteria

Exclusion Criteria:

  • The presence of open wounds, infections, skin lesions, or anatomical abnormalities in the areas where acupressure will be applied,
  • Discontinuing prescribed diabetes treatment or showing significant non-adherence to treatment regimen during the investigation period.
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    Acupressure Group

    Participants assigned to this group will receive acupressure treatment at points HT7, SP6, and ST36 by a trained researcher. The intervention will be administered once daily for six days, in addition to routine clinical care, with each session lasting approximately 15-20 minutes.

    Other: Acupressure

  • Sham comparator
    Sham Group

    Participants assigned to this group will receive sham acupressure, consisting of light pressure applied to non-acupoint areas near the same anatomical regions as the intervention group.

    Other: Sham Acupressure

  • Other
    Control Group (Routine Care)

    Participants assigned to this group will receive routine clinical care only and will not receive any additional intervention during the study period.

    Other: Routine care

Interventions

  • OtherAcupressure

    The acupressure intervention will be conducted in a designated room at the institution, once daily for 6 consecutive days, with each session lasting 15-20 minutes, totaling 6 sessions. During the first 3-5 minutes of each session, participants will be guided to the appropriate position and approached to ensure comfort. Acupressure will then be applied to a total of six points: both wrists (HT7) and both legs (ST36, SP6), with two points on each limb. Each of the six points will receive a 30-second preparation followed by 2 minutes of acupressure application

  • OtherSham Acupressure

    Participants in the placebo group will receive sham acupressure administered by the researcher in a quiet, designated room at the institution, once daily for 6 consecutive days, with each session lasting 15-20 minutes, totaling 6 sessions. Pressure will be applied to bony areas approximately 1.5-2 cm away from the HT7, SP6, and ST36 points, where no meridians pass. In the intervention group, evaluation will be made at the specified frequency, using the same measurement tools and the same measurement methods.

  • OtherRoutine care

    Participants will receive routine clinical care only and no additional intervention.

06

What researchers measure

Primary outcomes

  1. Blood Glucose

    Participants' blood glucose results will be assessed by capillary blood glucose measurement after at least 8-10 hours of fasting and 2 hours after meals. Measurement Process: Fasting blood sugar measurement: Fasting blood glucose measurement: This will be assessed before the start of the treatment, 24 hours after the completion of 3 sessions, and 24 hours after the completion of 6 sessions, after an 8-10 hour fast. Postprandial blood glucose measurement: Postprandial blood glucose levels will be assessed at the 2nd hour after the first bite of the meal. The first postprandial blood glucose assessment will take into account the first main meal after the first session, the second assessment will take into account the first main meal after the 3rd session, and the third assessment will take into account the postprandial blood glucose levels measured at the first main meal after the 6th session.

    Time frame: Baseline to Day 6

  2. Anxiety

    Anxiety levels will be assessed using the Spielberger State-Trait Anxiety Inventory (STAI). The Spielberger State-Trait Anxiety Inventory (STAI) is a validated self-report questionnaire used to assess anxiety. It consists of two distinct subscales: State Anxiety (STAI-S), which measures temporary anxiety related to the individual's current condition, and Trait Anxiety (STAI-T), which measures a person's general and long-term tendency to experience anxiety. Each subscale includes 20 items, with total scores ranging from 20 to 80. Higher scores indicate higher levels of anxiety, while lower scores indicate lower anxiety levels. Measurement Process: Before the intervention, the Spielberger State-Trait Anxiety Inventory (STAI) will be administered. The Spielberger State Anxiety Inventory will be applied to the participants half an hour after the first session, before the sixth session, and half an hour after the completion of the sixth session to assess their current anxiety levels.

    Time frame: Baseline to Day 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2026 to primary completion in Aug 2026, 6 months.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 6 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Feb 2026, on Oct 9, 2026.

Primary completion moved once since we started tracking on Sep 25, 2026: Apr 2026 → Aug 2026, on Oct 9, 2026.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Nov 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2026
First posted
Jan 21, 2026
StartActual
Feb 16, 2026was Jan 2026
Primary completionActual
Aug 24, 2026was Apr 2026
CompletionEst.
Dec 27, 2026was Oct 2026
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 9, 2026
Sites
Bolu Abant Izzet Baysal University is now Recruiting
Oct 9, 2026
Start date
Jan 24, 2026→Feb 16, 2026 (actual)
Oct 9, 2026
Primary completion
Apr 24, 2026→Aug 24, 2026 (actual)
Oct 9, 2026
Study completion
Oct 27, 2026→Dec 27, 2026
Nov 20, 2026
Eligibility
1 inclusion criterion edited, 2 added, 4 removed; 2 exclusion criteria added, 2 removed
What changed in the criteria
Inclusion criteria
  • RemovedVoluntarily agreeing to participate in the study,
  • EditedNot having anyThere should be no hearing, speech, or vision impairmentsproblems that would interfere withhinder the exchange and communication of the information,
  • RemovedHaving a Mini-Mental State Examination (MMSE) score of 23 or higher for literate participants and 19 or higher for illiterate participants,
  • RemovedReceiving dietary treatment or oral antidiabetic medication for diabetes management,
  • RemovedHaving no skin irritation, ulceration, or other impairment of skin integrity at the application sites.
  • AddedSuccessfully passing the mini mental and cognitive assessment routinely performed in the clinic,
  • AddedContinuing routine diabetes treatment for the past month.
Exclusion criteria
  • RemovedInitiation of a new medication with potential effects on blood glucose levels in addition to the current treatment during the study period,
  • RemovedUse of insulin therapy for diabetes management.
  • AddedThe presence of open wounds, infections, skin lesions, or anatomical abnormalities in the areas where acupressure will be applied,
  • AddedDiscontinuing prescribed diabetes treatment or showing significant non-adherence to treatment regimen during the investigation period.
Oct 9, 2026
Interventions
Changed Placebo Sham Acupressure→Sham Acupressure. Arms added: Sham Group; arms removed: Placebo Group
Oct 9, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionBlood Glucose: how it is measured was reworded
Oct 9, 2026
Show all 2 updates
  1. Nov 20, 2026
    Study completion Oct 27, 2026→Dec 27, 2026
    + 1 other change: verification date
  2. Oct 9, 2026
    Not yet recruiting→Recruiting
    Bolu Abant Izzet Baysal University is now Recruiting
    Start date Jan 24, 2026→Feb 16, 2026 (now actual)
    Primary completion Apr 24, 2026→Aug 24, 2026 (now actual)
    Eligibility 1 inclusion criterion edited, 2 added, 4 removed; 2 exclusion criteria added, 2 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedVoluntarily agreeing to participate in the study,
    • EditedNot having anyThere should be no hearing, speech, or vision impairmentsproblems that would interfere withhinder the exchange and communication of the information,
    • RemovedHaving a Mini-Mental State Examination (MMSE) score of 23 or higher for literate participants and 19 or higher for illiterate participants,
    • RemovedReceiving dietary treatment or oral antidiabetic medication for diabetes management,
    • RemovedHaving no skin irritation, ulceration, or other impairment of skin integrity at the application sites.
    • AddedSuccessfully passing the mini mental and cognitive assessment routinely performed in the clinic,
    • AddedContinuing routine diabetes treatment for the past month.
    Exclusion criteria
    • RemovedInitiation of a new medication with potential effects on blood glucose levels in addition to the current treatment during the study period,
    • RemovedUse of insulin therapy for diabetes management.
    • AddedThe presence of open wounds, infections, skin lesions, or anatomical abnormalities in the areas where acupressure will be applied,
    • AddedDiscontinuing prescribed diabetes treatment or showing significant non-adherence to treatment regimen during the investigation period.
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionBlood Glucose: how it is measured was reworded
    Interventions Changed Placebo Sham Acupressure→Sham Acupressure. Arms added: Sham Group; arms removed: Placebo Group
    + 3 other changes: verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07356024
Responsible party
Saadet Can Çiçek (Associate Professor, Abant Izzet Baysal University) — Principal investigator
First posted
Jan 21, 2026
Start date
Feb 16, 2026
Primary completion
Aug 24, 2026
Completion
Dec 27, 2026 (estimated)
Last update
Nov 20, 2026

Study contacts

Saadet CAN ÇİÇEK
Contact
saadet.cancicek@ibu.edu.tr
+905062846936

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion